Introduction

NeuroAiD (MLC601 & MLC901)’s neuroprotective capabilities include limiting exaggerated calcium influx, decreasing excitotoxicity, reducing oxidative stress, and preventing glutamate-induced cell death. It has also been shown to facilitate synaptogenesis, neurogenesis, and neuroplasticity. However, its clinical efficacy has primarily been studied in the context of brain injuries, particularly stroke. NeuroAiD’s potential application in SCI remains largely untapped.

Case presentation

A 34-year-old male presented with C4 complete tetraplegia. Following surgical decompression and initial inpatient rehabilitation, he started consuming MLC901 two capsules three times daily at month 4 post injury for 6 months. He regained considerable neurological recovery following the supplementation. Apart from the improvement in the neurological level of injury, the patient exhibited motor recovery beyond the initial zone of partial preservation up to 24 months post injury.

Discussion

Our findings align with a recent animal study demonstrating MLC901’s potential to downregulate Vascular Endothelial Growth Factor (VEGF), a molecule known to increase vascular permeability and exacerbate tissue edema and infarction. In another animal study involving stroke-affected mice, MLC901 demonstrates the ability to promote neurological recovery by regulating the expression of proteins mediating angiogenesis, such as hypoxic inducible factor 1α, erythropoietin, angiopoietins 1 and 2, as well as VEGF. The anecdotal findings from this case report offer preliminary insights into NeuroAiD’s potential in facilitating recovery during post-acute and chronic phases of severe SCI, necessitating further exploration.

中文翻译：

---

NeuroAiD 促进完全性脊髓损伤的神经功能恢复：病例报告

介绍

NeuroAiD（MLC601 和 MLC901）的神经保护能力包括限制过度的钙流入、减少兴奋性毒性、减少氧化应激以及防止谷氨酸诱导的细胞死亡。它还被证明可以促进突触发生、神经发生和神经可塑性。然而，其临床疗效主要是在脑损伤（尤其是中风）的背景下研究的。 NeuroAiD 在 SCI 中的潜在应用在很大程度上尚未开发。

案例展示

一名 34 岁男性因 C4 完全性四肢瘫痪就诊。手术减压和初步住院康复后，他在受伤后第 4 个月开始每天服用 3 次 MLC901 胶囊，每次两粒，持续 6 个月。服用补充剂后，他的神经功能得到了显着恢复。除了损伤的神经系统水平有所改善外，患者在受伤后 24 个月内还表现出超出部分保留初始区域的运动恢复。

讨论

我们的研究结果与最近的一项动物研究相一致，该研究表明 MLC901 具有下调血管内皮生长因子 (VEGF) 的潜力，血管内皮生长因子 (VEGF) 是一种已知会增加血管通透性并加剧组织水肿和梗塞的分子。在另一项涉及中风小鼠的动物研究中，MLC901 证明了通过调节介导血管生成的蛋白质（例如缺氧诱导因子 1α、促红细胞生成素、血管生成素 1 和 2 以及 VEGF）的表达来促进神经功能恢复的能力。本病例报告的轶事发现初步了解了 NeuroAiD 在促进严重 SCI 急性期后和慢性期康复的潜力，因此有必要进一步探索。